Mimesis

Mimesis

We predict Human Health, in Silico.

Our Top Products

Termini e condizioni

Our Customers

Mimesis Srl

MIMESIS is an innovative startup and SpinOff of the University of Catania that applies computational models to the pharmaceutical/nutraceutical sector, allowing the simulation of phenomena of a structural-chemical-biological nature.

Mimesis offers the first generation of “In Silico” solutions to the biomedical industry and pharmaceutical companies to reduce time and costs in the research and development process of medicinal products.

Mimesis cares about ethics since the solutions adopted do not require the use of humans, leading to a potential reduction of the number of patients who take part in clinical studies.

The estimated cost required for the approval of a new drug by regulatory agencies (EMA and FDA) varies between 2 and 3 billion dollars and it takes at least 10 years before the drug arrives on the market.

OMS World Patient Safety Day and Mimesis Srl: an interview.

OMS World Patient Safety Day and Mimesis Srl: an interview. 17 September marks the 5th World Patient Safety Day (WPSD), promoted by the World Health... Read More "OMS World Patient Safety Day and Mimesis Srl: an interview."

Mimesis joins SMAU 2022

Mimesis Srl, a Sicilian start-up, spin-off of the University of Catania, is among the companies selected to join the SMAU event in Milan on October... Read More "Mimesis joins SMAU 2022"